IL-12/23, IL-23 inhibitors reduce risk for progression to inflammatory arthritis vs. TNFi

Patients with psoriasis treated with interleukin-12/23 or IL-23 inhibitors may be less likely to progress to inflammatory arthritis than those treated with TNF inhibitors, according to data published in The Lancet Rheumatology.
“Currently, the role of biological immunotherapy in delaying progression from psoriasis to psoriatic arthritis is unclear,” Shikha Singla, MD, of the department of rheumatology at the Medical College of Wisconsin, told Healio. “Prior to our study, four studies showed an association between the time to incident psoriatic arthritis when comparing

Patients with psoriasis treated with interleukin-12/23 or IL-23 inhibitors may be less likely to progress to inflammatory arthritis than those treated with TNF inhibitors, according to data published in The Lancet Rheumatology.
“Currently, the role of biological immunotherapy in delaying progression from psoriasis to psoriatic arthritis is unclear,” Shikha Singla, MD, of the department of rheumatology at the Medical College of Wisconsin, told Healio. “Prior to our study, four studies showed an association between the time to incident psoriatic arthritis when comparing